Mestinon

Pyridostigmine bromide, the active ingredient in Mestinon, is a cholinesterase inhibitor presented as an oral dosage form for oral use. It is used to improve neuromuscular transmission in patients with myasthenia gravis.

GNH USA supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mestinon is a cholinesterase inhibitor indicated for disorders of neuromuscular transmission.

Myasthenia gravis: enhances muscle strength by increasing acetylcholine availability at the neuromuscular junction.

Mestinon may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Nausea and vomiting - Diarrhea or abdominal cramps - Increased salivation or sweating - Muscle cramps or fasciculations - Dizziness or headache - Blurred vision

Serious or Rare Side Effects: - Cholinergic crisis (muscle weakness, respiratory failure) - Severe bronchospasm or airway obstruction - Cardiac arrhythmias (bradycardia, atrioventricular block) - Severe hypotension - Allergic reactions (rash, angioedema, anaphylaxis)

Before prescribing Mestinon, clinicians should consider several safety aspects.

Renal impairment: adjust dose based on renal function. Asthma or COPD: monitor for bronchospasm. Concurrent anticholinergic therapy: avoid abrupt discontinuation. Pregnancy and lactation: safety not established; weigh benefits against risks. Elderly patients: start with lower doses and titrate slowly. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Mestinon can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Anticholinergic agents (e.g., atropine, scopolamine): may negate therapeutic effect. - Succinylcholine: potentiates neuromuscular blockade. - Other cholinesterase inhibitors: risk of cholinergic excess.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may exacerbate bradycardia. - Magnesium supplements: can enhance neuromuscular transmission effects. - Certain antibiotics (e.g., fluoroquinolones): may increase risk of tendon disorders. - Diuretics: monitor electrolyte balance.